Vertex Pharmaceuticals Incorporated
Explore Vertex Pharmaceuticals
Core profile pages, annual revenue records, and related research hubs for this company.
Vertex Pharmaceuticals Incorporated
Explore Vertex Pharmaceuticals
Core profile pages, annual revenue records, and related research hubs for this company.
Company History
Founded 1989 in Boston, Massachusetts
Joshua Boger founded Vertex in 1989 with an emphasis on rational, structure-based drug design. The company spent years building scientific credibility before cystic fibrosis medicines turned it into one of the most valuable independent biotechnology companies. That founding DNA still matters: Vertex is more comfortable betting deeply on difficult biology than chasing broad primary-care categories.
Joshua Boger founded Vertex with a focus on rational drug design and serious disease biology.
KALYDECO became an important early cystic fibrosis breakthrough and established Vertex's CF franchise.
TRIKAFTA expanded Vertex's ability to treat many people with cystic fibrosis and became the central revenue engine.
Reshma Kewalramani became Vertex's CEO and President after serving in senior medical leadership.
CASGEVY brought Vertex into CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia.
Vertex reported $12.0 billion in 2025 total revenue, up 9% from 2024.